Novan Therapeutics, of Durham, N.C., reported that its topical nitric oxide drug candidate for the treatment of acne vulgaris, SB-204, demonstrated a statistically significant 20 percent differential vs. vehicle in the percent change of non-inflammatory (white heads and black heads) and inflammatory (larger red bumps and pustules) lesions at week 12 of a phase IIb study.